Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells

Luo, Yun; Ling, You; Guo, Wusheng; Pang, Jun; Liu, Weipeng; Fang, Youqiang; Wen, Xinqiao; Gao, Xin

doi:10.1016/j.jconrel.2010.07.108

Cited by 75 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cell cycle analysis indicated that the EGFR-specific uptake of the targeted CET MAb-DOCT-γ-PGA Nps was more efficient than that of the nontargeted DOCT-γ-PGA Nps by MKN-28 cells, thereby arresting the cells in the G2/M phase, disturbing the process of cell division, and further progressing the cancer cells into the death phase. 35,36,51 The in vitro assays demonstrated EGFR-specific uptake of targeted Nps, making DOCT available to the cells and inducing apoptotic cancer cell death. Altogether, the results from MTT assays, cell cycle analysis, mitochondrial membrane potential analysis and apoptosis analysis provide strong support to the idea that CET MAb conjugation could improve the therapeutic potential of Nps for EGFR +ve cancers.…”

Section: Discussionmentioning

confidence: 99%

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

Sreeranganathan

Uthaman

Sarmento

et al. 2017

IJN

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR), upregulated in gastric cancer patients, is an oncogene of interest in the development of targeted cancer nanomedicines. This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(γ-glutamic acid) (γ-PGA) nanoparticles (Nps) and evaluates the in vitro/in vivo effects on EGFR-overexpressing gastric cancer cells (MKN-28). Nontargeted DOCT-γ-PGA Nps (NT Nps: 110±40 nm) and targeted CET MAb-DOCT-γ-PGA Nps (T Nps: 200±20 nm) were prepared using ionic gelation followed by 1-Ethyl-3-(3-dimethyl aminopropyl)carbodiimide–N-Hydoxysuccinimide (EDC–NSH) chemistry. Increased uptake correlated with enhanced cytotoxicity induced by targeted Nps to EGFR +ve MKN-28 compared with nontargeted Nps as evident from MTT and flow cytometric assays. Nanoformulated DOCT showed a superior pharmacokinetic profile to that of free DOCT in Swiss albino mice, indicating the possibility of improved therapeutic effect in the disease model. Qualitative in vivo imaging showed early and enhanced tumor targeted accumulation of CET MAb-DOCT-γ-PGA Nps in EGFR +ve MKN-28–based gastric cancer xenograft, which exhibited efficient arrest of tumor growth compared with nontargeted Nps and free DOCT. Thus, actively targeted CET MAb-DOCT-γ-PGA Nps could be developed as a substitute to conventional nonspecific chemotherapy, and hence could become a feasible strategy for cancer therapy for EGFR-overexpressing gastric tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

Sreeranganathan

Uthaman

Sarmento

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Both docetaxel and the nanoparticles showed a sigmoidal dosedependent cytotoxic effect on PC3M cells, as previously described. 2 Longer incubation or increased concentration led to an overall decrease in cell viability. The scAb-conjugated nanoparticles showed a significantly antiproliferative advantage over scAb-free nanoparticles.…”

Section: In Vitro Cytotoxicity and Intracellular Docetaxel Concentrationmentioning

confidence: 99%

“…However, the application of docetaxel is compromised by its hydrophobic nature, nonselective toxicity, and propensity to induce multidrug resistance. 2 Moreover, it is difficult to determine the effects of cancer therapy owing to the lack of specific and sensitive assessment modalities in clinical practice. 3 Promisingly, multifunctional nanomedical platforms, by incorporating different capabilities and targeting strategies, are demonstrating potential sophistication, 4,5 and greatly improving cancer diagnosis and therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy

Gao¹,

Luo²,

Wang³

2012

IJN

Self Cite

View full text Add to dashboard Cite

Background:We designed dual-functional nanoparticles for in vivo application using a modified electrostatic and covalent layer-by-layer assembly strategy to address the challenge of assessment and treatment of hormone-refractory prostate cancer. Methods: Core-shell nanoparticles were formulated by integrating three distinct functional components, ie, a core constituted by poly(D,L-lactic-co-glycolic acid), docetaxel, and hydrophobic superparamagnetic iron oxide nanocrystals (SPIONs), a multilayer shell formed by poly(allylamine hydrochloride) and two different sized poly(ethylene glycol) molecules, and a single-chain prostate stem cell antigen antibody conjugated to the nanoparticle surface for targeted delivery. Results: Drug release profiles indicated that the dual-function nanoparticles had a sustained release pattern over 764 hours, and SPIONs could facilitate the controlled release of the drug in vitro. The nanoparticles showed increased antitumor efficiency and enhanced magnetic resonance imaging in vitro through targeted delivery of docetaxel and SPIONs to PC3M cells. Moreover, in nude mice bearing PC3M xenografts, the nanoparticles provided MRI negative contrast enhancement, as well as halting and even reversing tumor growth during the 76-day study duration, and without significant systemic toxicity. The lifespan of the mice treated with these targeted dual-function nanoparticles was significantly increased (Chi-square = 22.514, P , 0.0001). Conclusion: This dual-function nanomedical platform may be a promising candidate for tumor imaging and targeted delivery of chemotherapeutic agents in vivo.

show abstract

“…Taxotere Õ (Sanofi-Aventis, Bridgewater, NJ) is the only commercial formulation of DTX on the market, which contains polysorbate 80 and dehydrated alcohol. However, its clinical application is limited by its multidrug resistance (MDR), highly lipophilic and practically insoluble in water, and severe toxic side effects from DTX and its excipients (Bissett et al, 1993;Vaishampayan et al, 2008;Luo et al, 2010;Zhu et al, 2015;Zu et al, 2015). Therefore, strategies (such as novel combination therapies or nanocarriers delivery systems) to increase its anti-tumor efficacy and decrease its side effects are critically needed.…”

Section: Introductionmentioning

confidence: 99%

Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activityin vitroandin vivo

Wang²,

et al. 2015

View full text Add to dashboard Cite

Chinese medicine is one nano-sized drug delivery system promising to generate synergistic anticancer effects, to maximize the treatment effect, and to overcome multi-drug resistance. The purpose of this study is to construct lipid-polymer hybrid nanoparticles (LPNs) as nanomedicine for co-encapsulation of DTX and curcumin (CUR). Methods: DTX and CUR co-encapsulated LPNs (DTX-CUR-LPNs) were constructed. DTX-CUR-LPNs were evaluated in terms of particles size, zeta potential, drug encapsulation, and drug delivery. The cytotoxicity of the LPNs was evaluated on PC-3 human prostate carcinoma cells (PC3 cells) by MTT assays. In vivo anti-tumor effects were observed on the PC3 tumor xenografts in mice.Results: The particle size of DTX-CUR-LPNs was 169.6 nm with a positive zeta potential of 35.7 mV. DTX-CUR-LPNs showed highest cytotoxicity and synergistic effect of two drugs in tumor cells in vitro. In mice-bearing PC-3 tumor xenografts, the DTX-CUR-LPNs inhibited tumor growth to a greater extent than other contrast groups, without inducing any obvious side effects. Conclusion: According to these results, the novel nanomedicine offers great promise for the dual drugs delivery to the prostate cancer cells, showing the potential of synergistic combination therapy for prostate cancer.

show abstract

Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells

Cited by 75 publications

References 32 publications

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy

Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activityin vitroandin vivo

Contact Info

Product

Resources

About

Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells

Cited by 75 publications

References 32 publications

In vivo evaluation of cetuximab-conjugated poly(&gamma;-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

In vivo evaluation of cetuximab-conjugated poly(&gamma;-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy

Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activityin vitroandin vivo

Contact Info

Product

Resources

About

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts